Single agent treatment with BRAF inhibitors such as vemurafenib and dabrafenib have demonstrated improved survival for patients with V600EBRAF mutant melanoma and are currently approved by the US Food and Drug Administration for treatment [13]. This evidence concerns the gene BRAF and melanoma.